Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus

References

• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant. 2014;14:11–44.
   PubMed Web of Science ®Google Scholar
• Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc. 1998;30:1216–1218.
   Web of Science ®Google Scholar
• Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834–841.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775–782.
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997;63:977–983.
   PubMed Web of Science ®Google Scholar
• Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant. 2014;14 Suppl 1:69–96.
   Google Scholar
• Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int. 2005;18:1121–1133.
   PubMed Web of Science ®Google Scholar
• Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769–776.
   PubMed Web of Science ®Google Scholar
• Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation. 2009;88:736–746.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897–903.
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Ishida H, Tanabe T, et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013;96:198–204.
   PubMed Web of Science ®Google Scholar
• Krämer BK1, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010;10:2632–2643.
   PubMed Web of Science ®Google Scholar
• Cabello M, García P, González-Molina M, et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc. 2010;42:3038–3040.
   Web of Science ®Google Scholar
• Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009;9:2505–2513.
   PubMed Web of Science ®Google Scholar
• Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7:595–608.
   PubMed Web of Science ®Google Scholar
• Ho ET, Wong G, Craig JC, Chapman JR. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation. 2013; 95:1120–1128.
   PubMed Web of Science ®Google Scholar
• Alloway RM, Mulgaonkar S, Ueda K, Cohen D, Kaplan B. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant. Volume 11, Issue Supplement s2, pages 213–527. Conference: April, 2011.
   Web of Science ®Google Scholar
• Masutani K, Tsuchimoto A, Haruyama N, et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. Transplant Proc. 2014;46:395–399.
   PubMed Web of Science ®Google Scholar
• Jelassi ML, Lefeuvre S, Karras A, Moulonguet L, Billaud EM. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. Transplant Proc. 2011;43:491–494.
   Web of Science ®Google Scholar
• Andrés A, Delgado-Arranz M, Morales E, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc. 2010;42:3034–3037.
   Google Scholar
• Wlodarczyk Z, Ostrowski M, Mourad M, et al. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial. Ther Drug Monit. 2012;34:143–147.
   PubMed Web of Science ®Google Scholar
• Kitada H, Okabe Y, Nishiki T, et al. One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant. Exp Clin Transplant. 2012;10:561–567.
   PubMed Web of Science ®Google Scholar
• Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71:391–402.
   PubMed Web of Science ®Google Scholar
• Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc. 2009;41:2115–2117.
   PubMed Web of Science ®Google Scholar
• Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation. 2012;94:1013–1019.
   PubMed Web of Science ®Google Scholar
• Ishida K, Ito S, Tsuchiya T, Imanishi Y, Deguchi T. Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up. Cent European J Urol. 2013;66:344–349.
   Google Scholar
• Niioka T, Kagaya H, Miura M, et al. Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol. 2013;69:1659–1665.
   Web of Science ®Google Scholar
• Takahashi K, Abe R, Usuki S, So M. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. Transplant Proc. 2014;46:406–410.
   Web of Science ®Google Scholar
• Fanous H, Zheng R, Campbell C, et al. A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study. Clin Kidney J. 2013;6:45–49.
   Google Scholar
• van Hooff JP, Alloway RR, Trunecka P, Mourad M. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant. 2011;25:E1–E12.
   PubMed Web of Science ®Google Scholar
• Schenker P, Klein T, Kruger B, et al. Modified release tacrolimus in de novo immunosuppression after simultaneous pancreas-kidney transplantation – a first single-center experience. Transplant Proc. 2009;41:2573–2575.
   PubMed Web of Science ®Google Scholar
• Abecassis MM, Seifeldin R, Riordan ME. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. Transplant Proc. 2008;40:1443–1445.
   Web of Science ®Google Scholar
• Trunečka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10:2313–2323.
   PubMed Web of Science ®Google Scholar
• Fischer L, Trunecka P, Gridelli B, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl. 2011;17:167–177.
   Web of Science ®Google Scholar
• Mita A, Ikegami T, Masuda Y, et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. Transplant Proc. 2014;46:794–796.
   Web of Science ®Google Scholar
• Ortiz de Urbina J, Valdivieso A, Matarranz A, et al. Advagraf de novo in liver transplantation: a single-center experience. Transplant Proc. 2011;43:724–725.
   Google Scholar
• Charco R, Caralt M, Llado L, et al. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients. Transplantat Proc. 2011;43:718–723.
   Web of Science ®Google Scholar
• Uemoto S, Abe R, Horike H, So M. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. Transplant Proc. 2014;46:749–753.
   Web of Science ®Google Scholar
• Marubashi S, Wada H, Kobayashi S, et al. Once-daily prolonged-release tacrolimus in de novo liver transplantation: a single center cohort study. Hepatogastroenterology. 2012;59:1184–1188.
   Google Scholar
• Sugawara Y, Miyata Y, Kaneko J, et al. Once-daily tacrolimus in living donor liver transplant recipients. Biosci Trends. 2011;5:156–158.
   Web of Science ®Google Scholar
• Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11:1965–1971.
   PubMed Web of Science ®Google Scholar
• Slatinska J, Rohal T, Wohlfahrtova M, Viklicky O. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience. Transplant Proc. 2013;45:1491–1496.
   Google Scholar
• Kurnatowska I, Krawczyk J, Oleksik T, Nowicki M. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. Transplant Proc. 2011;43:2954–2956.
   Web of Science ®Google Scholar
• Sabbatini M, Garofalo G, Borrelli S, et al. Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence. 2014;8:73–81.
   PubMed Web of Science ®Google Scholar
• Wu SW, Tsai HC, Tsai PY, Hung TW, Chang HR, Lian JD. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients. Swiss Med Wkly. 2013;143:w13850.
   Web of Science ®Google Scholar
• Ma MK, Kwan LP, Mok MM, Yap DY, Tang CS, Chan TM. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. Ren Fail. 2013;35:942–945.
   PubMed Web of Science ®Google Scholar
• Sessa A, Esposito A, Iavicoli G, et al. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus. Transplant Proc. 2012;44:1901–1906.
   Web of Science ®Google Scholar
• van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit. 2012;34:46–52.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Hama K, Katayama H, et al. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. Transplant Proc. 2012;44:124–127.
   Google Scholar
• Lauzurica R, Morales JM, van Hooff J; Study Investigators. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus. Transpl Int. 2012;25:48–55.
   Google Scholar
• Uchida J, Kuwabara N, Machida Y, et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. Transplant Proc. 2012;44:128–133.
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Jenssen T, Hartmann A, et al. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant. 2011;26:3767–3772.
   Web of Science ®Google Scholar
• Kolonko A, Chudek J, Wiecek A. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation. Transplant Proc. 2011;43:2950–2953.
   Web of Science ®Google Scholar
• Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet. 2011;50:451–459.
   PubMed Web of Science ®Google Scholar
• Iaria G, Sforza D, Angelico R, et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. Transplant Proc. 2011;43:1028–1029.
   Web of Science ®Google Scholar
• de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation. 2010;90:523–529.
   PubMed Web of Science ®Google Scholar
• Glick L, Shamy F, Nash M, et al. A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity. Transplant Res. 2014;3:7.
   Google Scholar
• Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc. 2009;41:2323–2325.
   Web of Science ®Google Scholar
• Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc. 2010;42:1317–1319.
   Web of Science ®Google Scholar
• Tinti F, Mecule A, Poli L, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc. 2010;42:4047–4048.
   Web of Science ®Google Scholar
• Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011;91:566–569.
   PubMed Web of Science ®Google Scholar
• Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics. 2011;21:179–184.
   PubMed Web of Science ®Google Scholar
• Calia R, Lai C, Aceto P, et al. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. Transplant Proc. 2011;43:1020–1023.
   PubMed Web of Science ®Google Scholar
• Mecule A, Tinti F, Poli L, et al. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen. Transplant Proc. 2011;43:1024–1027.
   PubMed Web of Science ®Google Scholar
• Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation. 2011;92:648–652.
   PubMed Web of Science ®Google Scholar
• Uchida J, Iwai T, Kabei K, et al. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. Transplant Proc. 2014;46:532–536.
   PubMed Web of Science ®Google Scholar
• Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007;83:1648–1651.
   PubMed Web of Science ®Google Scholar
• Bäckman L, Persson CA. An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. Ann Transplant. 2014;19:138–144.
   Web of Science ®Google Scholar
• Tsuchiya T, Ishida K, Ito S, Deguchi T. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. Transplant Proc. 2012;44:118–120.
   Web of Science ®Google Scholar
• Hatakeyama S, Fujita T, Yoneyama T, et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. Transplant Proc. 2012;44:121–123.
   Google Scholar
• Rostaing L, Sánchez-Fructuoso A, Franco A, Glyda M, Kuypers DR, Jaray J. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int. 2012;25:391–400.
   PubMed Web of Science ®Google Scholar
• Veroux M, Grosso G, Ekser B, Corona D, Giaquinta A, Veroux P. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. Transplantation. 2012;93:895–899.
   PubMed Web of Science ®Google Scholar
• van Boekel GA, Kerkhofs CH, Hilbrands LB. Treatment satisfaction in renal transplant patients taking tacrolimus once daily. Clin Ther. 2013;35:1821–1829. e1.
   Web of Science ®Google Scholar
• Wu MJ, Chang CH, Cheng CY, et al. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5. Transplant Proc. 2014;46:403–405.
   Google Scholar
• Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13:760–769.
   PubMed Web of Science ®Google Scholar
• Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37:867–870.
   PubMed Web of Science ®Google Scholar
• Muduma G, Odeyemi I, Pollock RF. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. J Med Econ. 2014;17:520–526.
   Google Scholar
• Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95:333–340.
   PubMed Web of Science ®Google Scholar
• Weiler N, Thrun I, Eberlin M, et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Transplant Proc. 2013;45:2321–2325.
   Web of Science ®Google Scholar
• Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. Transplant Proc. 2010;42:1322–1324.
   Web of Science ®Google Scholar
• Beckebaum S, Iacob S, Sweid D, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int. 2011;24:666–675.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Chen XY, Dai XJ, Leng XS, Zhong DF. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacol Sin. 2011;32:1419–1423.
   Web of Science ®Google Scholar
• Dopazo C, Rodriguez R, Llado L, et al. Successful conversion from twice-daily to once-daily tacrolimus in liver transplantation: observational multicenter study. Clin Transplant. 2012;26:E32–E37.
   PubMed Web of Science ®Google Scholar
• Dumortier J, Guillaud O, Boillot O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl. 2013;19:529–533.
   Google Scholar
• Giannelli V, Rossi M, Giusto M, et al. Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up. Eur Rev Med Pharmacol Sci. 2013;17:2718–2720.
   Web of Science ®Google Scholar
• Comuzzi C, Lorenzin D, Rossetto A, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc. 2010;42:1320–1321.
   Google Scholar
• Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005;37:1211–1213.
   PubMed Web of Science ®Google Scholar
• Eberlin M, Otto G, Kramer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc. 2013;45:2314–2320.
   PubMed Web of Science ®Google Scholar
• Valente G, Rinaldi L, Sgambato M, Piai G. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. Transplant Proc. 2013;45:1273–1275.
   Web of Science ®Google Scholar
• Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007;83:1639–1642.
   PubMed Web of Science ®Google Scholar
• Sańko-Resmer J, Boillot O, Wolf P, Thorburn D. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int. 2012;25:283–293.
   Web of Science ®Google Scholar
• Alloway RR, Eckhoff DE, Washburn WK, Teperman LW. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl. 2014;20:564–575.
   PubMed Web of Science ®Google Scholar
• Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc. 2009;41:2184–2186.
   Web of Science ®Google Scholar
• Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008;103:546–552.
   PubMed Web of Science ®Google Scholar